Researchers present highly anticipated IMPROVE-IT results
(Brigham and Women's Hospital) Results of the highly anticipated IMProved Reduction of Outcomes: Vytorin Efficacy International Trial, also known as IMPROVE-IT, co-led by researchers at Brigham and Women's Hospital and Duke Medicine, indicate that adding a second drug, ezetimibe, that blocks cholesterol absorption, resulted in a significant 6.4 percent reduction in the number of cardiovascular events.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news
More News: Cardiology | Cardiovascular | Cholesterol | Health | Heart | Hospitals | International Medicine & Public Health | Vytorin | Women | Zetia